This is a placebo controlled study comparing Rimonabant 5 mg per day for 90 days with placebo for the same period. Objective is to improve walking abilities of spinal cord injury individuals (incomplete lesions) and demonstrate that it is a safe treatment in spinal cord injury population.

Start Date01 Nov 2022

Sponsor / Collaborator

Hospital Nacional de Parapléjicos de Toledo

EUCTR2022-001522-30-ES

/ RecruitingPhase 2/3IIT

Effects of a CB1 receptor reverse antagonist/agonist (Rimonabant) on wandering ability in patients with incomplete spinal cord injuries

Start Date03 Oct 2022

Sponsor / Collaborator-

NCT05398913

/ CompletedPhase 1/2IIT

Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury: a Proof-of-concept Study

Randomized placebo-controlled safety and feasibility study with crossover design (3 arms). Placebo or Rimonabant 2.5mg or Rimonabant 5mg will be administered for 5 days. Exploratory efficacy will be tested using six-min walking test.

Start Date12 May 2021

Sponsor / Collaborator

Hospital Nacional de Parapléjicos de Toledo

100 Clinical Results associated with Rimonabant

100 Translational Medicine associated with Rimonabant

100 Patents (Medical) associated with Rimonabant

2,179

Literatures (Medical) associated with Rimonabant

01 Jan 2026·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Tetrahydrocannabinol (THC) and cannabidiol (CBD) inhibit androgen biosynthesis in H295R cells

Article

Author: Millius, Laura ; Brossaud, Anne-Claire ; Rossier, Michel F ; Zufferey, Fanny ; Hebinger, Doriane

The role of the cannabinoid system in human reproduction, and particularly in androgen biosynthesis, remains highly controversial. We recently observed significantly higher serum concentrations of testosterone and androstenedione in cannabis users than in the control group of a cohort of young Swiss men. To determine whether there is a direct causal relationship between cannabinoid exposure and androgen levels, we tested in vitro the effect of tetrahydrocannabinol (THC) and cannabidiol (CBD) on androgen biosynthesis in H295R cells. Modulation of steroidogenesis by phytocannabinoids and other agents was analysed in cell culture medium by liquid chromatography coupled to tandem mass spectrometry. Both THC and CBD significantly reduced in vitro DHEA, androstenedione and testosterone production by H295R cells in a concentration-dependent manner. The inhibitory action of cannabinoids was rapid and affected principally late steps of steroidogenesis. It was not prevented by rimonabant, a specific antagonist of the CB1 cannabinoid receptor. In addition, CBD (but not THC) appeared to affect the steroidogenic step involving the CYP17A1 enzyme. These results exclude a direct stimulation of steroidogenesis by phytocannabinoids in vivo as a putative mechanism for the positive association observed between cannabis use and blood androgen concentration in young men. Alternative explanations are discussed. Given that cannabis is frequently consumed by men of reproductive age, a better understanding of THC and CBD action on the reproductive system seems highly relevant in the context of the decline in male fertility observed in the general population.

01 Jan 2026·Ophthalmology science

Topical WIN 55 212-2 Confers Long-Term Intraocular Pressure–Independent Neuroprotection in the DBA/2J Mouse Model of Glaucoma

Author: Aiello, Francesco ; Porciatti, Vittorio ; Chou, Tsung-Han ; Adornetto, Annagrazia ; Nucci, Carlo ; Russo, Rossella ; Bagetta, Giacinto ; Korsch, Mascha Louisa ; Gallo Afflitto, Gabriele

Objective:

To evaluate the neuroprotective efficacy of topical WIN 55 212-2 (WIN) in the DBA/2J mouse model of chronic glaucoma.

Design:

Preclinical controlled study.

Subjects:

Ninety 6-month-old DBA/2J mice (180 eyes) grouped in Untreated (UN), WIN 1%, or WIN 1% + rimonabant (RIM).

Methods:

In vivo recordings were performed at 6 (T6), 8 (T8), and 10 (T10) months. Two broken-stick generalized estimating equation models were fitted: model 1 treated Intraocular Pressure (IOP) as a covariate; model 2 treated IOP as an explicit predictor. Retinal lysates underwent Western blotting (LC3-II, p62, Parkin, Optineurin, RNA-binding protein with multiple splicing (RBPMS), α-spectrin breakdown products [SBDPs]), and untargeted proteomics for exploratory mechanistic granularity assessment.

Main Outcome Measures:

Pattern electroretinogram (PERG), IOP, flash ERG (FERG), and photopic negative response amplitudes as well as ganglion cell complex (GCC) thickness.

Results:

At T8, IOP was 11.5 ± 1.4 mmHg in WIN compared to 22.0 ± 2.0 mmHg in UN and 21.7 ± 2.3 mmHg in RIM (P < 0.001). Similar results were observed at T10 (WIN: 19.4 ± 3.0 mmHg; UN: 23.4 ± 2.0 mmHg; RIM: 22.7 ± 3.2 mmHg) (P < 0.001). Statistically significant differences in PERG amplitude were observed among groups at both T8 and T10. In model 1, WIN-treated eyes demonstrated a 6.1 μV higher PERG amplitude at T10 (P < 0.001). Model 2 showed no significant WIN×IOP×T10 interaction (P = 0.757), suggesting that WIN-mediated protection is largely independent of IOP. Time-dependent decline in FERG was similar among groups. Photopic negative response amplitudes and GCC thickness decreased in all groups, with significant intergroup differences favoring WIN at both T8 and T10 (both P < 0.001). Molecularly, WIN reduced LC3-II by 35% at T10 without p62 accumulation, doubled Parkin and lowered Optineurin at T8, and markedly blunted RBPMS downregulation and SBDP accumulation (SBDP-120 kDa: -65% at T10). Proteomics identified 15 downregulated proteins in WIN retinas associated with relief of lysosomal antiprotease and Ca²⁺-stress pathways and enhanced autophagy-mitophagy flux.

Conclusions:

Topical WIN 1% transiently lowers IOP, preserves retinal ganglion cell function, and attenuates structural and molecular degeneration in a seemingly cannabinoid receptor 1-dependent and IOP-independent fashion, thus representing a promising neuroprotective strategy for glaucoma.

Financial Disclosures:

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

03 Dec 2025·NEUROREPORT

2-Linoleoylglycerol decreased seizure through the regulation of 5-hydroxytryptamine 1A receptor and G protein-coupled receptor 55 interaction in mice

Article

Author: Jabborov, Abdulaziz ; Yun, Jaesuk ; Gu, Sun Mi

Background:

Epilepsy is a central nervous system disorder characterized by abnormal brain activity, leading to seizures or periods of unusual behavior, sensations, and, in some cases, loss of awareness. Cannabidiol, a phytocannabinoid, has recently gained approval as an adjunctive seizure treatment, partly through modulation of G protein–coupled receptor 55 (GPR55), transient receptor potential vanilloid 1, and 5-hydroxytryptamine (5-HT) receptors. Similar to phytocannabinoids, endocannabinoids may also possess therapeutic potential for seizure management; however, no studies have investigated the effects of the endocannabinoid 2-linoleoylglycerol (2-LG). In the present study, we investigated the effects of 2-LG on pentylenetetrazol (PTZ)-induced seizures in mice.

Methods:

Mice were pretreated with 0 (vehicle), 15, or 30 mg/kg 2-LG intraperitoneally, and saline or 60 mg/kg PTZ was administered 30 min later. Vehicle, WAY-100635 (0.01 mg/kg), or rimonabant (1 mg/kg) were administered 30 min before 2-LG (30 mg/kg) administration, and then saline or 60 mg/kg PTZ was administered 30 min later.

Results:

Administration of 2-LG (30 mg/kg) significantly reduced seizure scores induced by PTZ. In addition, pretreatment with the 5-HT 1A receptor antagonist WAY-100635 reversed the 2-LG antiseizure effect. We also demonstrated that PTZ-induced fluorescence intensity of the GPR55 ligand T1117 in the hippocampus was decreased by 2-LG treatment, and this effect was reversed by WAY-100635 pretreatment. Similarly, the cannabinoid receptor type 1 inverse agonist rimonabant inhibited the antiseizure activity of 2-LG, although it did not significantly affect T1117 fluorescence.

Conclusion:

These results suggest that 2-LG exerts an antiseizure effect through interactions between the 5-HT 1A receptor and GPR55.

News (Medical) associated with Rimonabant

12 Nov 2025

·www.globenewswire.com

Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Presented robust CRB-701 clinical data at ESMO 2025 - 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 HNSCC registrational study planned to start mid-2026Completed $75 million public offering, extending cash runway into 2028Expected to complete CRB-913 SAD/MAD study and initiate Ph1b study in obese patients in Q4 2025 NORWOOD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended September 30, 2025. “This has been a productive period for Corbus, led by the presentation of CRB-701 data at ESMO 2025,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “We are encouraged by the clinical responses observed in HNSCC and cervical cancer from a patient population that was heavily pre-treated with other therapies and look forward to aligning with the FDA to find the most expedient path forward. We also continue to advance our CB1 inverse agonist, CRB-913, for the treatment of obesity and expect to report SAD/MAD data and initiate a Phase 1b dose-ranging study in obese, non-diabetic patients before the end of 2025. Finally with the closing of a $75 million public offering this month, our cash position is strong and will fund operations into 2028.” Key Corporate and Program Updates CRB-701 for the treatment of solid tumors, is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio (DAR) of 2 using monomethyl auristatin E (MMAE) as the payload. Dose optimization data from the Phase 1/2 study was presented as a poster at the 2025 European Society for Medical Oncology Congress (ESMO 2025). The Company also hosted a KOL event during ESMO 2025 to review and discuss the data. The event featured insights from leading HNSCC experts: Ari Rosenberg, MD – University of Chicago, Glenn Hanna, MD – Dana-Farber Cancer Institute, and Cesar Augusto Perez Batista, MD – Sarah Cannon Research Institute. Efficacy Data presented at ESMO 2025 demonstrated an objective response rate (ORR) of 33.3% and corresponding disease control rate (DCR) of 75.0% for HNSCC at 2.7 mg/kg and an ORR of 47.6% and corresponding DCR of 61.9% for the 3.6 mg/kg.Clinical responses were seen in patients pre-treated with EGFR inhibitors, including petosemtamab and cetuximab.Clinical responses were seen even in patients with low Nectin-4 expressions in line with the differentiated mechanism of action of CRB-701.Early clinical efficacy signals in cervical and bladder cancer appear encouraging with ORRs at 3.6 mg/kg of 37.5% and 55.6%, respectively. Safety Overall, CRB-701 demonstrated a favorable safety and tolerability profile with no grade 4 or 5 treatment- related adverse events.The most common treatment emergent adverse events (TEAEs) at a frequency of >15% were dysgeusia (18.6%), anemia (21.0%), fatigue (21.6%), alopecia (24.0%) and keratitis (32.3%).Grade 3 treatment-related adverse events were reported in 18.0% of patients.Notably, the rate of peripheral neuropathy was low at 8.4% (all Grade 1 or 2), based on a broad, standardized MedRA category search.The discontinuation rate related to CRB-701 was low at 6.0%. The Company plans to meet with the U.S. Food and Drug Administration (FDA) in the first quarter of 2026 to review the data and expects to initiate a Phase 2/3 registrational study by mid-2026. The FDA has granted Fast Track designations to CRB-701 for the treatment of HNSCC and relapsed or refractory metastatic cervical cancer. CRB-913 is a second generation, highly peripherally restricted, oral small molecule CB1 receptor inverse agonist drug candidate designed for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss but the previous class of such drug candidates was abandoned due to potential neuropsychiatric adverse event risks. CRB-913 is a member of a new class of peripherally restricted CB1 inverse agonists designed to have reduced brain penetration. The Company is on track to complete the CRB-913 single ascending dose and multiple ascending dose (SAD/MAD) study and to initiate Phase 1b study in obese, non-diabetic patients by the end of this year.CRB-913’s pre-clinical data demonstrates CRB-913 is markedly more peripherally restricted than either monlunabant or rimonabant. CRB-913 has a brain-to-plasma ratio 50 times lower than rimonabant and is 15 times more peripherally restricted than monlunabant. CRB-601 is a potent and selective anti-αvβ8 integrin monoclonal antibody (mAB) designed to block the activation of latent TGFβ in the tumor micro-environment to treat solid tumors. The first participant was dosed in December 2024 and the Phase 1 dose escalation study is ongoing.A study-in-progress poster was presented at the 2025 Society for Immunotherapy of Cancer (SITC). Financial Results for the Quarter Ended September 30, 2025 The Company reported a net loss of approximately $23.3 million, or a net loss per basic and diluted share of $1.90, for the three months ended September 30, 2025, compared to a net loss of $13.8 million, or a net loss per basic and diluted share of $1.15, for the three months ended September 30, 2024. Operating expenses increased by $8.9 million to approximately $24.4 million for the three months ended September 30, 2025, compared to approximately $15.5 million for the three months ended September 30, 2024. The increase was primarily attributable to an increase in clinical development expenses. As of September 30, 2025, the Company had $104.0 million of cash, cash equivalents, and investment on hand. Since the end of the third quarter ended September 30, 2025, the Company raised a total of $73.8 million in net proceeds from the issuance of 4,976,510 shares of common stock from an underwritten public offering and ATM sales. The Company believes it has sufficient cash to fund operations into 2028 based on current operating plans and assumptions regarding clinical timelines and planned expenditures. About Corbus Corbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. INVESTOR CONTACTS: Sean MoranChief Financial OfficerCorbus Pharmaceuticalssmoran@corbuspharma.com Dan FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com Corbus Pharmaceuticals Holdings, Inc.Condensed Consolidated Statements of Operations and Comprehensive Loss(in thousands, except share and per share amounts)(Unaudited) For the Three MonthsEnded September 30, For the Nine MonthsEnded September 30, 2025 2024 2025 2024 Operating expenses: Research and development $20,860 $10,808 $51,689 $23,435 General and administrative 3,557 4,697 11,655 12,681 Total operating expenses 24,417 15,505 63,344 36,116 Operating loss (24,417) (15,505) (63,344) (36,116) Other income (expense), net: Interest and investment income, net 1,125 1,903 4,120 4,531 Interest expense — (381) — (1,872) Other (expense) income, net (50) 200 1,242 2,778 Total other income, net 1,075 1,722 5,362 5,437 Net loss $(23,342) $(13,783) $(57,982) $(30,679) Net loss per share, basic and diluted $(1.90) $(1.15) $(4.73) $(2.92) Weighted average number of common shares outstanding, basic and diluted 12,307,298 12,014,700 12,250,315 10,490,981 Comprehensive loss: Net loss $(23,342) $(13,783) $(57,982) $(30,679) Other comprehensive income (loss): Change in unrealized gain (loss) on marketable debt securities 36 595 (38) 208 Total other comprehensive income (loss) 36 595 (38) 208 Total comprehensive loss $(23,306) $(13,188) $(58,020) $(30,471) Corbus Pharmaceuticals Holdings, Inc.Condensed Consolidated Balance Sheets(in thousands, except share and per share amounts) September 30, 2025(Unaudited) December 31, 2024 ASSETS Current assets: Cash and cash equivalents $26,983 $17,198 Investments 76,999 131,864 Restricted cash 285 285 Prepaid expenses and other current assets 3,304 3,629 Total current assets 107,571 152,976 Restricted cash 385 385 Property and equipment, net 201 385 Operating lease right-of-use assets 1,357 2,133 Total assets $109,514 $155,879 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $2,740 $4,786 Accrued expenses 12,578 5,426 Operating lease liabilities, current 1,742 1,606 Total current liabilities 17,060 11,818 Operating lease liabilities, noncurrent 307 1,633 Total liabilities 17,367 13,451 Stockholders’ equity Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $0.0001 par value; 300,000,000 shares authorized, 12,534,853 and 12,179,482 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 1 1 Additional paid-in capital 627,024 619,285 Accumulated deficit (534,875) (476,893)Accumulated other comprehensive (loss) gain (3) 35 Total stockholders’ equity 92,147 142,428 Total liabilities and stockholders’ equity $109,514 $155,879

Phase 1Financial StatementClinical ResultFast TrackADC

06 Oct 2025

·endpoints.news

Skye’s cannabinoid drug fails in mid-stage obesity trial

Skye Bioscience’s obesity shot has failed in a mid-stage trial, adding to the evidence that cannabinoid receptor 1 inhibitors have little effect in the disease. Nimacimab, as Skye’s antibody is known, did not improve weight loss over placebo in the Phase 2a study when used as a monotherapy, the company said Monday. Patients taking the drug lost just 1.5% of their body weight at 26 weeks (just over six months). Those given a placebo lost even less (0.3%), but the difference was not statistically significant. Speaking at an investor conference in September, Skye’s CEO Punit Dhillon said the company had guided towards weight loss of 5% to 8% at 26 weeks, adding that the company was “very confident about that.” On Monday, though, Skye said that a pharmacokinetic analysis showed lower-than-expected drug exposure, suggesting that the 200 mg weekly dose used in the trial was “suboptimal.” The company’s share price $SKYE fell more than 60% before the opening bell. The trial, named Cbeyond, also had an arm testing nimacimab in combination with Novo Nordisk’s Wegovy. This regimen cut patients’ weight by 13.2% at week 26, but did not reach statistical significance versus the control arm of Wegovy monotherapy, which yielded weight loss of 10.3%. Skye called the additional weight loss in the combination arm “clinically meaningful.” It added that patients in the combo arm had a significantly better ratio of lean mass to fat mass versus both the placebo and Wegovy monotherapy groups. The biotech claimed that this finding “supports potential further studies to evaluate combinations of nimacimab and incretin-based therapies.” Nimacimab had “placebo-like tolerability,” with 27% of subjects taking the drug having gastrointestinal adverse events, compared with 29.5% on placebo. GI events were seen in 57.1% of those in the Wegovy combination cohort, versus 66.7% with Wegovy alone. No neuropsychiatric concerns were raised, with no increase in anxiety, insomnia or depression among nimacimab recipients. The study had an overall discontinuation rate of 27%, with 3.7% of patients quitting due to side effects. Most of those who left the trial due to side effects had been given placebo. Skye said it would look at dosing the drug higher in “potential future clinical trials.” But cross-trial efficacy comparisons with other obesity therapies show that nimacimab is a long way behind competing drugs. Novo Nordisk’s cannabinoid receptor 1 (CB1) blocker pill monlunabant was much more effective than nimacimab in Phase 2, with patients losing 6.4% of their weight after four months. Even so, the readout was seen as a disappointment . The drug remains in Novo’s pipeline, but no active studies are listed in the federal clinical trials register. Another small biotech, Corbus Pharmaceuticals, is investigating this mechanism in obesity. Corbus kicked off a Phase 1 study of its pill, named CRB-913, in March, and early data could come this year. The only other CB1 drug used for obesity was Sanofi’s Acomplia, which was approved in Europe nearly 20 years ago. However, Sanofi had to pull Acomplia from the market in 2008 after it was linked with serious psychiatric disorders. But if CB1 drugs reach market again, they won’t just compete with each other — they’ll also have to go up against the much more effective class of GLP-1-based drugs. Weight loss at 26 weeks was around 10% and 15% on the pivotal trials of Wegovy and Eli Lilly’s Zepbound, respectively. Investigational products like Lilly’s triple agonist retatrutide and Roche’s GLP-1/GIP agonist CT-388 have demonstrated weight loss of around 18% to 19% at 24 weeks. So far, no CB1 inhibitor has got near this level of efficacy, and it is not clear that there is demand for a GLP-1/CB1 combination that is only marginally more effective. Editor’s note: This article was updated to note Skye Bioscience’s share price drop.

Clinical ResultPhase 2Drug ApprovalPhase 1Phase 3

06 May 2025

·www.globenewswire.com

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumorsSAD/MAD study on schedule for completion in Q3 2025 for the anti-obesity CB1 inverse agonist CRB-913Dose escalation study on schedule for completion in Q4 2025 for the anti-αvβ8 integrin mAB-CRB-601 in solid tumors NORWOOD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2025. “During the first quarter of 2025, we continued to advance our pipeline by presenting encouraging CRB-701 Phase 1 solid tumor data from U.S. and U.K. sites at ASCO GU and initiating the CRB-913 Phase 1 study in obesity,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “We look forward to reporting clinical data from all three of our pipeline programs in the 2nd half of this year including: RP2D data from our Nectin-4 ADC (CRB-701), SAD/MAD data from our anti-obesity CB1 inverse agonist (CRB-913) and the first ever dose escalation data in solid tumors for the anti- αvβ8 mAb (CRB-601). The data will be very informative in determining the next steps in our oncology and obesity programs and will form the basis of discussions with regulatory authorities and other relevant parties.” Key Corporate and Program Updates CRB-701 for the treatment of solid tumors, is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using monomethyl auristatin E (MMAE) as the payload. Phase 1 dose escalation data was presented as a poster presentation at ASCO GU in February 2025. The Phase 1/2 study (NCT06265727) is being conducted by Corbus in the U.S. and Europe.Study Highlights: Safety, tolerability and PK comparable to SYS6002 Phase 1 Chinese data presented at ASCO 2024 by our partner CSPC.Low levels of peripheral neuropathy and skin toxicity were observed in both studies.Clinical responses were seen in urothelial (mUC) and cervical cancer participants in both studies.First-time treatment in participants with head and neck squamous cell carcinoma (HNSCC) yielded multiple responses. Dose optimization is on-going with dosing at 2.7 mg/kg and 3.6 mg/kg cohorts in HNSCC, cervical and mUC tumors. The Company expects to complete dose optimization and establish a recommended Phase 2 dose (RP2D) in the fourth quarter of 2025.The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer. CRB-913 is a second generation, highly peripherally restricted, oral small molecule CB1 receptor inverse agonist drug designed for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss. The Company dosed the first participant in the Phase 1 SAD/MAD study in March 2025, which is scheduled to be completed in Q3 2025. The Phase 1b dose-range finding study is expected to commence in the fourth quarter of 2025 and scheduled for completion in the second half of 2026. The Company’s pre-clinical data demonstrates CRB-913 is markedly more peripherally restricted than either monlunabant or rimonabant. CRB-913 has a brain to plasma ratio fifty times lower than rimonabant and is fifteen times more peripherally restricted than monlunabant. CRB-601 is a potent and selective anti-αvβ8 integrin monoclonal antibody (mAB) designed to block the activation of latent TGFβ in the tumor micro-environment to treat solid tumors. The first participant was dosed in December 2024 in the dose escalation portion of a Phase 1 study which is being conducted in the U.S. and Europe and scheduled for completion in Q4 2025. Financial Results for the Quarter Ended March 31, 2025 The Company reported a net loss of approximately $17.0 million, or a net loss per basic and diluted share of $1.39, for the three months ended March 31, 2025, compared to a net loss of $6.9 million, or a net loss per basic and diluted share of $0.83, for the three months ended March 31, 2024. Operating expenses increased by $10.2 million to approximately $19.8 million for the three months ended March 31, 2025, compared to approximately $9.6 million for the three months ended March 31, 2024. The increase was primarily attributable to an increase in clinical development expenses. As of March 31, 2025, the Company had $132.8 million of cash, cash equivalents, and investment on hand, which is expected to fund operations through Q2 2027 based on planned expenditures. About CorbusCorbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. INVESTOR CONTACT: Sean MoranChief Financial OfficerCorbus Pharmaceuticalssmoran@corbuspharma.com Bruce MackleManaging DirectorLifeSci Advisors, LLCbmackle@lifesciadvisors.com ---tables to follow--- Corbus Pharmaceuticals Holdings, Inc.Condensed Consolidated Statements of Operations and Comprehensive Loss(in thousands, except share and per share amounts)(Unaudited) For the Three MonthsEnded March 31, 2025 2024 Operating expenses: Research and development $15,642 $5,762 General and administrative 4,133 3,861 Total operating expenses 19,775 9,623 Operating loss (19,775) (9,623)Other income (expense), net: Interest and investment income, net 1,681 1,028 Interest expense — (839)Other income, net 1,116 2,535 Total other income, net 2,797 2,724 Net loss $(16,978) $(6,899)Net loss per share, basic and diluted $(1.39) $(0.83)Weighted average number of common shares outstanding, basic and diluted 12,202,092 8,310,508 Comprehensive loss: Net loss $(16,978) $(6,899)Other comprehensive loss: Change in unrealized loss on marketable debt securities (58) (328)Total other comprehensive loss (58) (328)Total comprehensive loss $(17,036) $(7,227) Corbus Pharmaceuticals Holdings, Inc.Condensed Consolidated Balance Sheets(in thousands, except share and per share amounts) March 31, 2025(Unaudited) December 31, 2024 ASSETS Current assets: Cash and cash equivalents $18,900 $17,198 Investments 113,887 131,864 Restricted cash 285 285 Prepaid expenses and other current assets 4,288 3,629 Total current assets 137,360 152,976 Restricted cash 385 385 Property and equipment, net 304 385 Operating lease right-of-use assets 1,882 2,133 Total assets $139,931 $155,879 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $4,068 $4,786 Accrued expenses 5,902 5,426 Operating lease liabilities, current 1,650 1,606 Total current liabilities 11,620 11,818 Operating lease liabilities, noncurrent 1,205 1,633 Total liabilities 12,825 13,451 Stockholders’ equity Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2025 and December 31, 2024. — — Common stock, $0.0001 par value; 300,000,000 shares authorized,12,232,853 and 12,179,482 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 1 1 Additional paid-in capital 620,999 619,285 Accumulated deficit (493,871) (476,893)Accumulated other comprehensive (loss) gain (23) 35 Total stockholders’ equity 127,106 142,428 Total liabilities and stockholders’ equity $139,931 $155,879

Phase 1Financial StatementADCFast Track

100 Deals associated with Rimonabant

External Link

KEGG	Wiki	ATC	Drug Bank
D05731	Rimonabant	A08AX01	DB06155

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	European Union	Sanofi-Aventis Ltd.	19 Jun 2006
Obesity	Iceland	Sanofi-Aventis Ltd.	19 Jun 2006
Obesity	Liechtenstein	Sanofi-Aventis Ltd.	19 Jun 2006
Obesity	Norway	Sanofi-Aventis Ltd.	19 Jun 2006
Overweight	European Union	Sanofi-Aventis Ltd.	19 Jun 2006
Overweight	Iceland	Sanofi-Aventis Ltd.	19 Jun 2006
Overweight	Liechtenstein	Sanofi-Aventis Ltd.	19 Jun 2006
Overweight	Norway	Sanofi-Aventis Ltd.	19 Jun 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus	Phase 3	Spain	-	20 Dec 2007
Metabolic Dysfunction Associated Steatohepatitis	Phase 3	Portugal	-	24 Sep 2007
Type 2 diabetes mellitus in obese	Phase 3	Japan	Sanofi	01 Apr 2007
Abdominal Obesity Metabolic Syndrome	Phase 3	Austria	Sanofi	01 Dec 2006
Abdominal Obesity Metabolic Syndrome	Phase 3	Belgium	Sanofi	01 Dec 2006
Abdominal Obesity Metabolic Syndrome	Phase 3	Brazil	Sanofi	01 Dec 2006
Abdominal Obesity Metabolic Syndrome	Phase 3	Bulgaria	Sanofi	01 Dec 2006
Abdominal Obesity Metabolic Syndrome	Phase 3	Canada	Sanofi	01 Dec 2006
Abdominal Obesity Metabolic Syndrome	Phase 3	Czechia	Sanofi	01 Dec 2006
Abdominal Obesity Metabolic Syndrome	Phase 3	Denmark	Sanofi	01 Dec 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00656487 (SCCAN, CTgov)	Phase 2	Marijuana Abuse \| Cannabis withdrawal	66	Rimonabant (Rimonabant)	vmvrjxmwes(jbhfnpznyj) = zvtgmewhoc mivefbbalu (hrfwrzzyzm, 5.59) View more	-	15 May 2017
				placebo (Placebo)	vmvrjxmwes(jbhfnpznyj) = iqqolsfieg mivefbbalu (hrfwrzzyzm, 7.87) View more
NCT00547118 (CTgov)	Phase 2	Schizoaffective disorder \| Schizophrenia \| Smoking ... View more	17	Rimonabant (Rimonabant)	pvvpaebbyr(gvfakmkcbs) = lpbldzmkuw xvysqnhzyq (cwcsctrtfc, 7.5) View more	-	27 Feb 2015
				Placebo (Placebo)	pvvpaebbyr(gvfakmkcbs) = ykpoiywemg xvysqnhzyq (cwcsctrtfc, 4.6) View more
NCT00263042 (Pubmed \| Lancet)	Phase 3	-	18,695	Rimonabant 20 mg	zengmwssbl(shrbbvtwnu) = 3038 [33%] vs 2084 [22%] vpncdwsysf (pqryvtidhq ) View more	-	14 Aug 2010
				Placebo
NCT00458718 (Pubmed \| Addiction)	Phase 3	Smoking Cessation	755	Rimonabant + Nicotine patch	dkkxxhrmpm(viwpomight) = zidpizcqbz zilvrmrqdl (rnayeckudw )	Positive	01 Feb 2009
				Rimonabant only	dkkxxhrmpm(viwpomight) = gwegzuwsrg zilvrmrqdl (rnayeckudw )
NCT00124332 (Pubmed \| JAMA)	Phase 3	Coronary Artery Disease \| Obesity, Abdominal	839	Rimonabant	wqmfyoearh(ocyebdlxlq) = hchoeyvncj epjsipmaxj (lavxxsurzc, -0.04% - 0.54%) View more	-	02 Apr 2008
				Placebo	wqmfyoearh(ocyebdlxlq) = oxivlrubpm epjsipmaxj (lavxxsurzc, 0.22% - 0.80%) View more
NCT00029835 (RIO-Lipids, Pubmed \| N Engl J Med)	Phase 3	Dyslipidemias \| Overweight	1,036	Placebo	yfkrtvfqml(zsukxipglc) = virxoimgfw nttwqgskys (byhemnbesn ) View more	-	17 Nov 2005
				Rimonabant 5 mg	yfkrtvfqml(zsukxipglc) = fqsnfmlslf nttwqgskys (byhemnbesn ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Rimonabant

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation